share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director HERSHBERG ROBERT

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director HERSHBERG ROBERT

Recursion Pharmaceuticals | 4：持股變動聲明-董事 HERSHBERG ROBERT
美股sec公告 ·  06/06 06:17
牛牛AI助理已提取核心訊息
Robert Hershberg, associated with Recursion Pharmaceuticals, Inc. [RXRX], completed a stock transaction on June 3, 2024. The transaction involved a grant of 13,097 shares of Class A Common Stock at no cost. Following the transaction, Hershberg's direct holdings in the company increased to a total of 51,716 shares. The grant is part of the company's compensation strategy and reflects the ongoing commitment to align the interests of its executives with those of shareholders.
Robert Hershberg, associated with Recursion Pharmaceuticals, Inc. [RXRX], completed a stock transaction on June 3, 2024. The transaction involved a grant of 13,097 shares of Class A Common Stock at no cost. Following the transaction, Hershberg's direct holdings in the company increased to a total of 51,716 shares. The grant is part of the company's compensation strategy and reflects the ongoing commitment to align the interests of its executives with those of shareholders.
與Recursion Pharmaceuticals，Inc. [RXRX]有關的Robert Hershberg於2024年6月3日完成了一筆股票交易。該交易涉及一次無償的13,097股A類普通股授予。交易後，Hershberg在該公司的直接持股增加至共51,716股。該授予是公司報酬策略的一部分，反映了公司與股東的利益一致的持續承諾。
與Recursion Pharmaceuticals，Inc. [RXRX]有關的Robert Hershberg於2024年6月3日完成了一筆股票交易。該交易涉及一次無償的13,097股A類普通股授予。交易後，Hershberg在該公司的直接持股增加至共51,716股。該授予是公司報酬策略的一部分，反映了公司與股東的利益一致的持續承諾。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。